Investors braced for a bumpy ride ahead of Savient Pharmaceuticals'
What analysts say:
- Buy, sell, or hold?: Half of analysts think investors should stand pat on Savient Pharmaceuticals. Analysts don't like Savient Pharmaceuticals as much as competitor Par Pharmaceutical overall. Seven out of nine analysts rate Par Pharmaceutical a buy compared to one out of eight for Savient Pharmaceuticals.
- Wall Street earnings expectations: The average analyst estimate is a loss of $0.39 per share. Estimates range from a loss of $0.45 to a loss of $0.35.
What our community says:
CAPS All-Stars are strongly supporting the stock, with 88.1% assigning it an outperform rating. Most of the community is in line with the All-Stars, with 93.3% giving it a rating of outperform. Fools feel positively about Savient Pharmaceuticals, though the message boards have been quiet lately, with only two posts in the past 30 days. Despite the majority sentiment in favor of Savient Pharmaceuticals, the stock has a middling CAPS rating of three out of five stars.
The company's gross margin shrank by 135 percentage points in the last quarter. Revenue rose 161.2% while cost of sales rose 988.8% to $4.6 million from a year earlier.
For all our Savient Pharmaceuticals-specific analysis, including earnings and beyond, add Savient Pharmaceuticals to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.